[artículo]
| Título : |
Results from 2 randomized, double blind, placebo controlled studies of the novel nk1 receptor antagonist casopitant in patients with major depressive disorder |
| Tipo de documento: |
texto impreso |
| Autores: |
Ratti Ratti, Autor ; Kevin Bellew, Autor ; Paolo Bettica, Autor |
| Fecha de publicación: |
2022 |
| Artículo en la página: |
pp. 727-733 |
| Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
| Palabras clave: |
Casopitant, GW679769, Antagonista de NK1, Ocupación del receptor, Depresión, Sueño |
| Resumen: |
Clinical study results for neurokinin (NK) receptor antagonists in the treatment of depression have been mixed, with Phase III studies failing to fulfill the early promise demonstrated in Phase II studies. Casopitant, a selective NK1 antagonist that achieves nearly complete receptor occupancy was studied in 2 randomized, placebo-controlled, double-blind,.. |
| Link: |
./index.php?lvl=notice_display&id=29345 |
in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 6 (Diciembre) . - pp. 727-733
[artículo] Results from 2 randomized, double blind, placebo controlled studies of the novel nk1 receptor antagonist casopitant in patients with major depressive disorder [texto impreso] / Ratti Ratti, Autor ; Kevin Bellew, Autor ; Paolo Bettica, Autor . - 2022 . - pp. 727-733. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 6 (Diciembre) . - pp. 727-733
| Palabras clave: |
Casopitant, GW679769, Antagonista de NK1, Ocupación del receptor, Depresión, Sueño |
| Resumen: |
Clinical study results for neurokinin (NK) receptor antagonists in the treatment of depression have been mixed, with Phase III studies failing to fulfill the early promise demonstrated in Phase II studies. Casopitant, a selective NK1 antagonist that achieves nearly complete receptor occupancy was studied in 2 randomized, placebo-controlled, double-blind,.. |
| Link: |
./index.php?lvl=notice_display&id=29345 |
|
Refinar búsquedaResults from 2 randomized, double blind, placebo controlled studies of the novel nk1 receptor antagonist casopitant in patients with major depressive disorder en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 6 (Diciembre)
